BioSpace News Archive

Aegle Therapeutics Corporation, a first-in-class biotechnology company developing extracellular vesicles as therapy, today announced the completion of a $6.5M Series A round of financing.

Prometheus Biosciences, Inc., (“Prometheus”) a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of inflammatory bowel disease (IBD), announced today the appointment of Olivier Laurent, Ph.D. as Chief Technology Officer

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, will provide an update on LPCN 1144, an oral product of bioidentical testosterone being evaluated for the treatment of non-cirrhotic, NASH at the H.C. Wainwright 4th Annual NASH Investor Conference,

ProterixBio, Inc. announced today commercial availability of the SARS-CoV-2 (RBD) IgG Antibody test, a semi-quantitative COVID-19 serology assay.

Scott Sigman, M.D., today announced the publication of a second case report demonstrating positive outcomes for a COVID-19 patient treated with laser therapy.

Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the company has closed a $17.5 million Series C financing.

Fast, easy-to-install system supports employee safety and health; employees use personal, battery-free fob to quickly scan their temperature for touch-free entry and contact tracing on large corporate campuses

Evolent Health, Inc. (NYSE: EVH) (the “Company” or “Evolent”), a health care company that delivers proven clinical and administrative solutions to payers and providers, will host a virtual Investor and Analyst Day today

Soliton, Inc., a medical device company with a novel and proprietary aesthetic platform technology, announced that it has appointed Lippe Taylor Group as its consumer health public relations and customer engagement agency.

Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a strategic supply partnership with the Drugs for Neglected Disease Initiative (DNDi), a collaborative, patients’ needs-driven, non-profit drug research and development organization that is developing new treatments for neglected diseases